CAMBRIDGE, Mass.--(BUSINESS WIRE)--Curis, Inc. (NASDAQ: CRIS), a drug development company focused on developing proprietary targeted medicines primarily for cancer treatment, announced that a presentation entitled, “Efficacy data of GDC-0449, a systemic Hedgehog (Hh) pathway antagonist, in a first-in-human, first-in-class, phase I study with locally advanced (LA), multifocal (MF) or metastatic (met) basal cell carcinoma (BCC) patients (pts),” was given by Daniel D. Von Hoff, M.D. today at the American Association for Cancer Research (AACR) Annual Meeting 2008 in San Diego, California. GDC-0449 is being developed by Genentech under a collaboration agreement that Curis and Genentech entered into in June 2003.
